NCT06824701 - Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

January 31, 2032

Study Completion Date

January 31, 2033

Conditions

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions

DRUG

Tazemetostat

Tazemetostat will be self-administered BID as an oral treatment on a 28-day cycle.

DRUG

Zanubrutinib

Zanubrutinib will be self-administered BID as an oral treatment on a 28-day cycle.

DRUG

Rituximab

Rituximab or a biosimilar will be administered intravenously per standard of care.

DRUG

Obinutuzumab

Obinutuzumab will be administered intravenously on days 1, 8, 15 of cycle 1 and then day 1 of cycles 2 to 12.

Trial Locations (1)

RECRUITING

Huntsman Cancer Institute at University of Uta, Salt Lake City